Klinika Neurologii
Lublin
0 studies enrolling now · 1 studies all time
What they study most
Multiple Sclerosis, Relapsing-Remitting
Studies at this site
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
— Completed